ReviewAnnals of hematology2026
Central nervous system multiple myeloma: An update for 2026.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Central nervous system multiple myeloma (CNS-MM) is a rare yet highly aggressive plasma cell dyscrasia with a poor prognosis. CNS-MM represents a distinct clinical entity characterized by unique diagnostic challenges and therapeutic resistances. Conventional therapies have historically yielded dismal outcomes, with median survival measured in months. Modern diagnosis relies on integrating neurological symptoms, advanced CSF flow cytometry, and high-resolution imaging; however, unified diagnostic criteria remain lacking. In the modern era, multimodal strategies incorporating radiotherapy, BBB-penetrating agents, and immunotherapy have expanded treatment options. Bispecific antibodies and CAR-T therapy demonstrate unprecedented CNS-specific response rates, although data remain limited. This review synthesizes current evidence on CNS-MM epidemiology, risk factors, diagnostics, and therapeutics, highlighting emerging immunotherapeutic approaches and persistent knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.